KEGG   DRUG: Elapegademase
Entry
D11017                      Drug                                   
Name
Elapegademase (USAN/INN);
Elapegademase (genetical recombination) (JAN);
Elapegademase-lvlr;
Revcovi (TN)
Product
REVCOVI (Chiesi USA)
Sequence
AQTPAFNKPK VELHVHLDGA IKPETILYYG RKRGIALPAD TPEELQNIIG MDKPLSLPEF
LAKFDYYMPA IAGSREAVKR IAYEFVEMKA KDGVVYVEVR YSPHLLANSK VEPIPWNQAE
GDLTPDEVVS LVNQGLQEGE RDFGVKVRSI LCCMRHQPSW SSEVVELCKK YREQTVVAID
LAGDETIEGS SLFPGHVKAY AEAVKSGVHR TVHAGEVGSA NVVKEAVDTL KTERLGHGYH
TLEDTTLYNR LRQENMHFEV CPWSSYLTGA WKPDTEHPVV RFKNDQVNYS LNTDDPLIFK
STLDTDYQMT KNEMGFTEEE FKRLNINAAK SSFLPEDEKK ELLDLLYKAY GMPSPA
  Type
Peptide
Remark
Therapeutic category: 3959
ATC code: L03AX21
Product: D11017<JP/US>
Efficacy
Enzyme replacement (adenosine deaminase)
  Disease
Adenosine deaminase severe combined immune deficiency [DS:H02309]
  Type
Enzyme replacement therapy product
Target
ADA* [HSA_VAR:100v1] [HSA:100] [KO:K01488]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L03 IMMUNOSTIMULANTS
   L03A IMMUNOSTIMULANTS
    L03AX Other immunostimulants
     L03AX21 Elapegademase
      D11017  Elapegademase (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
  Elapegademase
   D11017  Elapegademase (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   395  Enzyme preparations
    3959  Others
     D11017  Elapegademase (USAN/INN); Elapegademase (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Adenosine deaminase
    ADA* [HSA_VAR:100v1]
     D11017  Elapegademase (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11017
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11017
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11017
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D11017
Other DBs
CAS: 1709806-75-6
PubChem: 348350489
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system